Table 1.
Peripherally-applied pharmaceutical drugs found to selectively inhibit hedonic eating.
| Physiological Messengers | Pharmacological Intervention | Drug | Species | References |
|---|---|---|---|---|
| Endocannabinoids Opioids Dopamine Gamma-aminobutyric acid Glutamate Glucagon-like peptide-1 Oxytocin |
CB1 receptor
inhibition MOR receptor inhibition D2/D3 receptor stimulation Reuptake inhibition GABAB receptor stimulation mGluR5 receptor inhibition NMDA receptor inhibition GLP-1 receptor stimulation Oxytocin receptor stimulation |
Rimonabant (SR 141716) AM 251, rimonabant Naltrexone Naltrexone Quinpirole Methylphenidate Baclofen MTEP Memantine Exendin-4 Liraglutide Liraglutide Oxytocin |
Marmosets ♀ Rats Rats Humans Rats Rats Rats Baboons Rats Rats Rats Humans Humans |
[73] [77, 78] [93] [104, 105] [127] [148] [253, 257] [267] [183] [82] [182] [307] [366] |
CB1 receptor – cannabinoid 1 receptor; MOR receptor – mu opioid receptor; D receptor – dopamine receptor; GABAB receptor – gamma-aminobutyric acid B receptor; mGluR5 receptor – metabotropic glutamate receptor 5; NMDA receptor – N-methyl-D-aspartate receptor; GLP-1 receptor – glucagon-like peptide-1 receptor